Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,477.57 60.04 0.42%
TOPIX 1,169.19 2.60 0.22%
HANG SENG 22,760.24 64.23 0.28%

FDA Approvals, New Appointments, Positive Litigation Outcomes and Partnerships - Research Report on Edwards Lifesciences,



FDA Approvals, New Appointments, Positive Litigation Outcomes and Partnerships
  - Research Report on Edwards Lifesciences, Illumina, Teva, Alere, and Dr.
                                   Reddy's

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 26, 2013

NEW YORK, September 26, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Edwards
Lifesciences Corp. (NYSE: EW), Illumina, Inc. (NASDAQ: ILMN), Teva
Pharmaceutical Industries Ltd. (ADR) (NYSE: TEVA), Alere Inc. (NYSE: ALR) and
Dr. Reddy's Laboratories Limited (ADR) (NYSE: RDY). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Edwards Lifesciences Corp. Research Report

On September 24, 2013, The Washington Post reported that the U.S. Food and
Drug Administration (FDA) approved revised labeling for Edwards Lifesciences'
Sapien heart valve. As stated in the Washington Post release, the original
labeling on the device instructed surgeons to thread the valve into place
through a major artery that runs from the leg up to the heart, while with the
new labeling, FDA allows surgeons to choose from multiple methods of
implantation. The Washington Post further added that according to analysts
estimates, as many as 70,000 to 100,000 patients per year could eventually
receive the Sapien replacement valve. The Full Research Report on Edwards
Lifesciences Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-24/EW]

--

Illumina, Inc. Research Report

On September 23, 2013, Illumina, Inc. (Illumina) announced that the Company
has appointed Dr. Richard Klausner as Senior Vice President and Chief Medical
Officer. According to the Company, in his role, Dr. Klausner will report to
Illumina's President and CEO, Jay Flatley and will be responsible for leading
the Company's strategies for advancing genomics into clinical medicine and
public health. The Company also informed that Dr. Klausner will become part of
Illumina's Executive Management Team, which is responsible for directing all
aspects of Company strategy, planning, and operations. Illumina stated that
prior to his new role, Dr. Klausner was the managing partner of the venture
capital firm, The Column Group. Jay Flatley, said, "Rick's expertise in
molecular biology, his experience in life sciences, and his roles in global
health policy make him uniquely suited to mobilize constituents around the use
of genomics within medical practice." The Full Research Report on Illumina,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-24/ILMN]

--

Teva Pharmaceutical Industries Ltd. (ADR) Research Report

On September 23, 2013, Teva Pharmaceutical Industries Ltd. (Teva) announced
that the U.S. District Court for the District of New Jersey has issued a
favorable drug ruling in the Company's patent infringement lawsuit against
Mylan, filed in October 2010, regarding  AZILECT (rasagiline tablets) patent
which covers methods of treating Parkinson's disease (PD). Teva stated that
the Court upheld validity of the Company's patent. Teva expects the Court to
enter Judgment that prevents Mylan from launching its generic version of
Azilect until the Company's patent expires in 2017. The Full Research Report
on Teva Pharmaceutical Industries Ltd. (ADR) - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-09-24/TEVA]

--

Alere Inc. Research Report

On September 23, 2013, Alere Inc. (Alere) announced that it is partnering with
"Malaria No More" on the Power of One campaign which will raise funds to
deliver life-saving tests and treatment to children in Africa. The Company
stated that the campaign will engage the global public and the companies to
help close the malaria treatment and testing gap in Africa using the latest
mobile, social, and e-commerce technologies. Alere added that every dollar
donated to the campaign will provide screening and treatment for a child in
Africa. The Company informed that in 2014 and 2015, it expects that more that
300 million treatments are needed to ensure that everyone with malaria has
access to the life-saving tools. Avi Pelossof, Global President of Infectious
Disease at Alere, said, "As the world's leading provider of rapid diagnostic
tests for malaria, Alere is deeply committed to working with partners such as
Malaria No More to prevent deaths from this devastating disease, one that
particularly strikes young children." The Full Research Report on Alere Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-24/ALR]

--

Dr. Reddy's Laboratories Limited (ADR) Research Report

On September 17, 2013, Dr. Reddy's Laboratories Limited (ADR) (Dr. Reddy's)
announced that Azactidine for Infection 100 mg/vial, which is a bioequivalent
generic version of VIDAZA (azacitidine for injection), was approved by the
U.S. Food and Drug Administration on September 16, 2013. Dr. Reddy's, stated
that according to IMS health data, the VIDAZA brand had sales of c.$378.5
million from US for the twelve months ended July 2013. The Company also
informed that it plans to launch Azactidine for Injection 100 mg/vial in the
near term. The Full Research Report on Dr. Reddy's Laboratories Limited (ADR)
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-24/RDY]

----    

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Investors' Reports

Contact: CONTACT PERSON: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement